Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia

Authors

Jeffrey Kingsley, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA 19140, U.S.A.
Keiichi Torimoto, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA 19140, U.S.A.
Tomoki Hashimoto, Barrow Aneurysm and AVM Research Center, Departments of Neurosurgery and Neurobiology, Barrow Neurological Institute, 350 W. Thomas Rd, Phoenix, AZ 85013, U.S.A.Follow
Satoru Eguchi, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA 19140, U.S.A.

Document Type

Article

Abstract

Sarcopenia is defined as the progressive and generalized loss of skeletal muscle mass and strength, which is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality. The etiology of sarcopenia has been postulated to be multifactorial with genetics, aging, immobility, nutritional deficiencies, inflammation, stress, and endocrine factors all contributing to the imbalance of muscle anabolism and catabolism. The prevalence of sarcopenia is estimated to range from 13 to 24% in adults over 60 years of age and up to 50% in persons aged 80 and older. As the population continues to age, the prevalence of sarcopenia continues to increase and is expected to affect 500 million people by the year 2050. Sarcopenia impacts the overall health of patients through limitations in functional status, increase in hospital readmissions, poorer hospital outcomes, and increase in overall mortality. Thus, there exists a need to prevent or reduce the occurrence of sarcopenia. Here, we explore the potential mechanisms and current studies regarding angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors on reducing the development of sarcopenia through the associated changes in cardiovascular function, renal function, muscle fiber composition, inflammation, endothelial dysfunction, metabolic efficiency, and mitochondrial function.

Keywords

ACE, ARB, Sarcopenia, angiotensin II

Medical Subject Headings

Aged; Aged, 80 and over; Angiotensin II (metabolism); Angiotensin Receptor Antagonists (therapeutic use); Angiotensin-Converting Enzyme Inhibitors (therapeutic use); Animals; Body Composition; Comorbidity; Female; Functional Status; Humans; Male; Middle Aged; Muscle, Skeletal (drug effects, metabolism, pathology, physiopathology); Renin-Angiotensin System (drug effects); Risk Factors; Sarcopenia (drug therapy, epidemiology, metabolism, physiopathology); Treatment Outcome

Publication Date

11-12-2021

Publication Title

Clinical science (London, England : 1979)

E-ISSN

1470-8736

Volume

135

Issue

21

First Page

2503

Last Page

2520

PubMed ID

34751393

Digital Object Identifier (DOI)

10.1042/CS20210719

Recommended Citation

Kingsley, Jeffrey; Torimoto, Keiichi; Hashimoto, Tomoki; and Eguchi, Satoru, "Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia" (2021). Translational Neuroscience. 1660.
https://scholar.barrowneuro.org/neurobiology/1660